ART Fertility Clinics: Comprehensive Company Profile

Background

Overview

ART Fertility Clinics, established in 2015 as an extension of IVI RMA Global under the brand name IVI Middle East, transitioned to its current identity in January 2020 following IVI RMA's divestment to Gulf Capital. Under the leadership of CEO Suresh Soni and Group Medical Director Prof. Dr. Human Fatemi, the organization has become a leading institute for human reproductive medicine in the Middle East.

Mission and Vision

The clinic's mission is to become the global reference standard for clinical outcomes, patient satisfaction, research, and teaching in human reproduction and genetics. Its vision emphasizes delivering world-class reproductive medicine services, stimulating research among its medical professionals, and achieving professional excellence in customer care.

Industry Significance

ART Fertility Clinics has distinguished itself through high success rates, proprietary research, and a commitment to patient-centric care, positioning it as a thought leader in the fertility sector. The clinic's expansion into India and plans for further growth in Europe and Asia underscore its significant role in the global fertility industry.

Key Strategic Focus

Core Objectives

• Clinical Excellence: Achieving high pregnancy and live birth rates through evidence-based practices.

• Research and Innovation: Conducting original research to advance reproductive medicine.

• Global Expansion: Extending services to new markets to address the growing demand for fertility treatments.

Areas of Specialization

• Comprehensive Fertility Treatments: Offering personalized treatments for both male and female infertility.

• Genetic Testing: Utilizing advanced genetic testing to enhance treatment outcomes.

Key Technologies Utilized

• AI-Enabled Equipment: Incorporating AI-enabled incubators and microscopes.

• Advanced Imaging: Employing 4D ultrasound machines for precise diagnostics.

• State-of-the-Art Laboratories: Maintaining clean rooms and advanced embryology labs to ensure optimal conditions for embryo development.

Primary Markets Targeted

• Middle East: Established clinics in Abu Dhabi, Dubai, Al Ain, and Muscat.

• India: Operational clinics in Delhi, Gurugram, Mumbai, Ahmedabad, Hyderabad, and Chennai, with plans for further expansion.

• Europe and Asia: Plans to launch several clinics during the second half of 2024.

Financials and Funding

Funding History

In January 2020, Gulf Capital invested over $100 million to acquire a controlling stake in ART Fertility Clinics, marking its largest equity investment to date.

Recent Funding Rounds

In March 2021, Gulf Capital announced a $30 million investment to support ART Fertility Clinics' expansion into India, aiming to establish 18 clinics over two years.

Notable Investors

• Gulf Capital: A leading growth markets alternative investment firm.

Utilization of Capital

• Infrastructure Development: Establishing new clinics in targeted regions.

• Technology Acquisition: Implementing advanced medical technologies and equipment.

• Research Initiatives: Funding ongoing research to enhance treatment protocols and outcomes.

Pipeline Development

Key Pipeline Candidates

• Clinic Expansion: Plans to open 20 additional clinics in India, other parts of Asia, and Europe within the next 18 months.

Stages of Development

• Operational Clinics: Existing clinics in the Middle East and India.

• Planned Clinics: Upcoming establishments in Europe and Asia.

Target Conditions

• Infertility Treatments: Addressing both male and female infertility through personalized treatment plans.

Timelines for Milestones

• 2021-2023: Establishment of 18 clinics in India.

• 2024-2025: Launch of clinics in Europe and Asia.

Technological Platform and Innovation

Proprietary Technologies

• Genetic Laboratory: Utilizing the latest Next-Generation Sequencing (NGS) systems for comprehensive genetic testing.

Significant Scientific Methods

• Evidence-Based Protocols: Implementing treatment protocols grounded in original research and clinical trials.

AI-Driven Capabilities

• AI-Enabled Equipment: Incorporating AI technologies in laboratory equipment to enhance diagnostic accuracy and treatment outcomes.

Leadership Team

Key Executives

• Suresh Soni: Global CEO, leading strategic initiatives and global expansion efforts.

• Prof. Dr. Human Fatemi: Group Medical Director, overseeing clinical operations and research activities.

• Dr. Laura Melado: Medical Director – Abu Dhabi, responsible for clinical services in the Abu Dhabi clinic.

• Dr. Carol Coughlan: Medical Director – Dubai, managing clinical operations in the Dubai clinic.

• Prof. Dr. Barbara Lawrenz: Senior IVF Consultant & Scientific Director, contributing to research and clinical excellence.

• Ibrahim Elkhatib: Group Director – Embryology, leading embryology services across clinics.

• Dr. Araz Raberi: Group Genomics Director, overseeing genetic testing and research.

• Prof. Dr. Mustafa Baris Ata: Professor of Obstetrics and Gynecology & Specialist in Reproductive Medicine, providing expert clinical care.